ABOUT US

Main Menu
Main Menu
LUKE BESHAR

Luke Beshar

Chairman

Luke Beshar is a seasoned biotechnology executive and financial expert with more than 35 years of general and financial management experience at various public and private companies. Mr. Beshar currently serves as Chairman of Board of Protara Therapeutics, Inc….
READ MORE

LUKE BESHAR

Chairman

Luke Beshar is a seasoned biotechnology executive and financial expert with more than 35 years of general and financial management experience at various public and private companies. Mr. Beshar currently serves as Chairman of Board of Protara Therapeutics, Inc., a publicly held company focused on immuno-oncology; Chairman of Board of Inotrem, an advanced clinical stage company developing TREM-1 targeting immunotherapies for acute and chronic inflammatory syndromes; and  director and chair of the audit committee of Omega Therapeutics, a publicly held company pioneering a new class of DNA-sequence-targeting mRNA-encoded therapeutics. Mr. Beshar served as a director at Trillium Therapeutics Inc., a publicly held immuno-oncology company, from 2014 until it was acquired by Pfizer in November 2021 and was chair of its audit and compensation committees.  Mr. Beshar served as a director and chair of audit committee of REGENXBIO Inc., a publicly held gene therapy company, from 2015 (pre-IPO) to 2021. Mr. Beshar served as Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a global biopharmaceutical company from November 2007 until it was acquired by Takeda (Shire plc) in February 2015 and Executive Vice President and Chief Financial Officer of Cambrex Corporation, a publicly held life sciences company, from 2002 to 2007.  Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia and is a Certified Public Accountant.

JESSE SHEFFERMAN

JESSE SHEFFERMAN

Co-founder, Director, Chief Executive Officer

Jesse Shefferman is a co-founder of Protara and has led the Company since its inception through the addition of two late-stage assets, the establishment of multiple late-stage development programs and its listing on NASDAQ in early 2020…
READ MORE

JESSE SHEFFERMAN

Co-founder, Director, Chief Executive Officer

Jesse Shefferman is a co-founder of Protara and has led the Company since its inception through the addition of two late-stage assets, the establishment of multiple late-stage development programs and its listing on NASDAQ in early 2020. Mr. Shefferman has spent over twenty years in the biopharma industry holding several strategic leadership and financial roles.

Prior to co-founding Protara, Mr. Shefferman was Vice President and Head of Business Development at Retrophin Inc., a leading rare diseases company where Jesse was a member of the executive leadership team and executed a number of company-defining transactions.

Prior to Retrophin, Mr. Shefferman served as Director, Strategy and Business Development at Vertex Pharmaceuticals, Inc., where he focused on hepatology and rare disease programs. Mr. Shefferman previously served as an investment banker with Barclays Capital and Lehman Brothers Inc., where he focused on providing strategic and financial advice to the management teams and boards of directors of numerous biopharmaceutical companies.

Mr. Shefferman holds an MBA and Certificate in Health Sector Management from Duke University and a B.A. in Accounting from Gordon College.

MICHAEL SOLOMON

MICHAEL SOLOMON, Ph.D.

Director

Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He currently serves as Chief Executive Officer and on the board of directors of Ribometrix, Inc…

READ MORE

MICHAEL SOLOMON, Ph.D.

Director

Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He currently serves as Chief Executive Officer and on the board of directors of Ribometrix, Inc., a company focused on targeting RNA with small molecules, and has over 20 years of experience in the biotech industry, with the last 14 years focused on creating and operating early-stage companies. Most recently, Dr. Solomon served as a Venture Partner at SV Health Investors from December 2016 until December 2018 and as Chief Operating Officer at Decibel Therapeutics, Inc., a biotech company focused on hearing disorders, from 2015 until 2016, where he led the creation of Decibel’s business plan and its capital raise of $52 million. Previously, he was Chief Operating Officer at Ember Therapeutics, Inc. from 2012 until 2015, and Chief Business Officer at Link Medicine Corporation, a CNS company that was sold to Astra Zeneca, from 2009 until 2012. Dr. Solomon was a Founder and Vice President of Discovery at Epizyme Therapeutics, Inc., and Vice President of Discovery at Hypnion, Inc., a sleep disorder company that was sold to Eli Lilly and Company in 2007. He began his career at Millennium Pharmaceuticals, where he was a project leader for multiple programs. Dr. Solomon holds a B.S. in Chemistry from the University of Massachusetts, Amherst; a Ph.D. in Organic Chemistry from the University of Wisconsin; and completed postdoctoral work in synthetic organic chemistry at Scripps.

BARRY FLANNELLY

BARRY FLANNELLY, Pharm.D

Director

Dr. Barry Flannelly has served on Protara’s board of directors since July 2020 and is currently the Executive Vice President and General Manager, North America at Incyte…

READ MORE

BARRY FLANNELLY, Pharm.D

Director

Dr. Barry Flannelly has served on Protara’s board of directors since July 2020 and is currently the Executive Vice President and General Manager, North America at Incyte Corporation. Dr. Flannelly joined Incyte as Executive Vice President, Business Development and Strategic Planning, in August 2014 and was appointed General Manager, U.S., in June 2015. He began his career in the pharmaceutical and biotech industry at Rhone-Poulenc Rorer in 1997, which later became Sanofi S.A. Dr. Flannelly has held roles of increasing responsibility in medical affairs, strategic planning, and commercial operations at Novartis Pharmaceuticals Corporation, Abraxis Oncology, Onyx Pharmaceuticals, Inc., and Nektar Therapeutics. Throughout his career, he has led the successful launch of several products in the U.S. and worldwide for oncology indications including breast, prostate, lung, and gastric cancers. Prior to joining the industry, Dr. Flannelly served as Manager of Pharmacy Services at The Johns Hopkins Oncology Center.

He earned his D. Pharm. from the University of Maryland School of Pharmacy, his M.B.A. from the University of Baltimore, and his B.S. in Pharmacy from Massachusetts College of Pharmacy.

Cynthia Smith

CYNTHIA SMITH

Director

Cynthia Smith has served on Protara’s board of directors since January of 2021. She has more than 20 years of broad leadership experience within the healthcare industry.

READ MORE

CYNTHIA SMITH

Director

Cynthia Smith has served on Protara’s board of directors since January of 2021. She has more than 20 years of broad leadership experience within the healthcare industry. Most recently she has served as chief commercial officer and a member of the executive team of ZS Pharma Inc. (acquired by AstraZeneca Plc), where she led efforts to transition the company from the development stage to a commercial enterprise.

Prior to joining ZS Pharma, Ms. Smith served as vice president, market access and commercial development at Affymax, Inc. Earlier, she held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before beginning her career in the biopharmaceutical industry, Ms. Smith served as a healthcare policy analyst in the White House Office of Management and Budget. Ms. Smith earned a B.A. from the University of North Carolina at Chapel Hill, an M.B.A. from the Wharton School and an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University.

She currently serves on the Board of Directors at Spero Therapeutics Inc., Dicerna Pharmaceuticals Inc., and Akebia Therapeutics Inc., and as an advisor to EQRx, Inc. and Catalys Pacific.

Roger Garceau, MD

ROGER GARCEAU, M.D.

Director

Dr. Roger Garceau has served on Protara’s board of directors since January 2019 and has more than 30 years of broad pharmaceutical industry experience in drugs, biologics and combination drug/device products for…

READ MORE

ROGER GARCEAU, M.D.

Director

Dr. Roger Garceau has served on Protara’s board of directors since January 2019 and has more than 30 years of broad pharmaceutical industry experience in drugs, biologics and combination drug/device products for orphan and non-orphan indications, both in the U.S. and internationally. He previously served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. from December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. At NPS, Dr. Garceau led two successful orphan products through regulatory filings, Advisory Committee meetings and registrations. Previously, he served in several other managerial positions with NPS Pharmaceuticals, Sanofi S.A. and Pharmacia Corporation. He serves on the board of directors of Enterome S.A., and Entera Bio Ltd. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. He holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.

Jane Huang

JANE HUANG, M.D.

Director

Dr. Jane Huang has served on Protara’s board of directors since June 2021. Dr. Huang is an experienced biotech executive and proven leader throughout the development lifecycle…

READ MORE

JANE HUANG, M.D.

Director

Dr. Jane Huang has served on Protara’s board of directors since June 2021. Dr. Huang is an experienced biotech executive and proven leader throughout the development lifecycle of multiple oncology therapeutics globally. She currently serves as President and Chief Medical Officer of Prelude Therapeutics Inc. From September 2016 until March 2022, Dr. Huang served as Chief Medical Officer, Hematology at BeiGene, Ltd. At BeiGene, Dr. Huang oversaw hematology drug development and played a key role in the first approval of tislelizumab, BeiGene’s PD-1 inhibitor, as well as zanubrutinib, BeiGene’s BTK inhibitor. Prior to joining BeiGene, Dr. Huang was Vice President and Head of Development at Acerta Pharma B.V., where she oversaw global clinical development of the BTK inhibitor acalabrutinib. Previously, she served as Group Medical Director at Genentech (a member of the Roche Group), where she played a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. Dr. Huang also currently serves as a Clinical Assistant Professor (adjunct), Thoracic Oncology, at Stanford University. She received her B.S. degree in Biological Sciences from Stanford University and her M.D. from University of Washington School of Medicine. She is board certified in hematology, oncology, and internal medicine, and she completed her residency in Internal Medicine and fellowships in Hematology and Oncology at Stanford University.

Greg Sargen

GREG SARGEN

Director

Gregory Sargen has served on Protara’s board of directors since November 2019 and is a licensed Certified Public Accountant (inactive) with extensive experience working within the healthcare industry. Mr. Sargen served as Chief Financial Officer…

READ MORE

GREG SARGEN

Director

Gregory Sargen has served on Protara’s board of directors since November 2019 and is a licensed Certified Public Accountant (inactive) with extensive experience working within the healthcare industry. Mr. Sargen served as Chief Financial Officer and Executive Vice President, Corporate Development and Strategy of Cambrex Corporation from January 2017 until January 2020, following the December 2019 acquisition of Cambrex by a private equity company. Previously, he served as Executive Vice President and Chief Financial Officer at Expanets, Inc., and Vice President of Finance – Chemicals Manufacturing Division at Fisher Scientific International Inc. Prior to that, Mr. Sargen held senior positions with Merck & Co., Inc., Heat and Control, Inc. and Deloitte & Touche LLP. His board experience includes his current role as a director of Avid Bioservices, Inc., Umoja Biopharma, Inc. and Kindeva Drug Delivery, L.P. Mr. Sargen holds a B.A. in Accounting from Pennsylvania State University and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.

RICHARD LEVY

RICHARD LEVY, M.D.

Director

Dr. Richard Levy has served on Protara’s board of directors since December 2019 and has more than 25 years of experience in the pharmaceutical and biotechnology industries…

READ MORE

RICHARD LEVY, M.D.

Director

Dr. Richard Levy has served on Protara’s board of directors since December 2019 and has more than 25 years of experience in the pharmaceutical and biotechnology industries. He is board certified in internal medicine and gastroenterology. Dr. Levy currently serves on the boards of directors of various biopharmaceutical companies, including Madrigal Pharmaceuticals, Inc., Kodiak Sciences, Inc. and Kiniksa Pharmaceuticals, Ltd. Additionally, Dr. Levy served as a part-time Senior Advisor for Baker Bros. Advisors, L.P. from December 2016 until May 2019. Prior to Dr. Levy’s board experience, he held an array of executive positions in the pharmaceutical industry, including in drug development, regulatory affairs and pharmacovigilance, clinical research, as well as medical and commercial strategy. He served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation from January 2009 until he retired in April 2016, and as Senior Vice President of Drug Development at Incyte from August 2003 until January 2009. His extensive industry experience includes positions at Celgene Corporation, DuPont Pharmaceuticals Company, Sandoz AG and Novartis AG. Dr. Levy holds a B.A. in Biology from Brown University and an M.D. from the University of Pennsylvania School of Medicine. He completed his training in internal medicine at the Hospital of the University of Pennsylvania and a fellowship in gastroenterology and hepatology at the University of California, Los Angeles.

OUR STORY
Scroll to Top